AstraZeneca PLC
Change company Symbol lookup
Select an option...
AZN AstraZeneca PLC
ALLE Allegion PLC
INTU Intuit Inc
TSLA Tesla Inc
TWLO Twilio Inc
JHS John Hancock Income Securities Trust
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
LPSN LivePerson Inc
Go

Health Care : Pharmaceuticals | Large Cap Blend
Based in United Kingdom
Company profile

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Premarket

Last Trade
Delayed
$54.55
-0.24 (-0.44%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$54.79
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
28,157

10-day average volume:
5,574,523
28,157

Avail Medsystems Honored by Goldman Sachs for Entrepreneurship

10:00 am ET October 14, 2021 (PR Newswire) Print

Goldman Sachs (NYSE:GS) is recognizing Daniel Hawkins, CEO of Avail Medsystems, as one of the 100 Most Intriguing Entrepreneurs of 2021 at its Builders + Innovators Summit in Healdsburg, California.

https://mma.prnewswire.com/media/1660150/Daniel_Hawkins__Avail.jpg

Goldman Sachs selected Hawkins as one of 100 entrepreneurs from multiple industries to be honored at the two-day event. Hawkins is the founder and CEO of Avail Medsystems, a medical technology company creating a network where medical expertise sharing can occur between healthcare professionals and experts to and from the operating room anytime, anywhere. Over the past 25 years in the medical technology field, his mission has been to identify and close gaps that prevent patients from getting the best possible healthcare. He is an inventor on over 140 patents and applications and has held roles in both large and emerging companies, including Advanced Cardiovascular Systems, Inc., Endologix, Restore Medical, EnteroMedics, and Intuitive Surgical. Hawkins is a co-founder of Calibra Medical, acquired by Johnson & Johnson, and founder of Shockwave Medical, Inc. (NASDAQ: SWAV). He has an MBA from Stanford University and a BS in Economics from The Wharton School of the University of Pennsylvania. Hawkins was also honored by Goldman Sachs as one of its Top 100 Most Intriguing Entrepreneurs in 2017.

"I'm pleased to be chosen as one of the 100 Most Intriguing Entrepreneurs by Goldman Sachs," said Daniel Hawkins, CEO of Avail Medsystems. "Thanks to the selection committee for the honor of re-joining an elite group of entrepreneurs from a range of industries, who, in their specific markets, are building world-class organizations that bring value to their customers, employees and investors."

"Innovation doesn't happen just anywhere; it thrives where there's a wide range of thoughts and perspectives," said David M. Solomon, Chairman & CEO of Goldman Sachs. "One of our great strengths is our ability to bring together people from different walks of life and to spark conversations today that will lead to breakthroughs tomorrow. The leaders we've chosen to highlight at our Builders + Innovators Summit are truly remarkable, and we are pleased to recognize Daniel Hawkins as one of this year's most intriguing entrepreneurs."

In addition to honoring 100 entrepreneurs, the summit consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About Avail Medsystems

Avail Medsystems is a pioneering technology company. Its product the Avail System is designed to seamlessly connect interventionalists and surgeons to remote experts and device industry representatives to facilitate collaboration during medical procedures. Avail's immersive hardware and software platform enables instant, HIPAA-HITECH protected, two-way audio/visual communication with high-definition video and surgical imaging views and telestration capabilities. Avail offers a SaaS-based pricing model, without a capital equipment purchase, and includes a comprehensive approach to service and support. For more information about Avail Medsystems, visit Avail.io and follow us on Twitter, Facebook, Instagram and LinkedIn.

Avail Media ContactShannon Severinoshannon@pascalecommunications.com 412-608-2393

https://mma.prnewswire.com/media/1529188/Screen_Shot_2021_06_08_at_7_29_18_PM_Logo.jpg

https://c212.net/c/img/favicon.png?sn=NE39814&sd=2021-10-14

View original content to download multimedia:https://www.prnewswire.com/news-releases/avail-medsystems-honored-by-goldman-sachs-for-entrepreneurship-301400128.html

SOURCE Avail Medsystems

https://rt.prnewswire.com/rt.gif?NewsItemId=NE39814&Transmission_Id=202110141000PR_NEWS_USPR_____NE39814&DateId=20211014

comtex tracking

COMTEX_395189887/1005/2021-10-14T10:00:45

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.